Thomas, M. (2017). A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer. Investigational new drugs, 35(3), . https://doi.org/10.1007/s10637-017-0450-3
Chicago-Zitierstil (17. Ausg.)Thomas, Michael. "A Randomized, Open-label, Multicenter, Phase II Study Evaluating the Efficacy and Safety of BTH1677 (1,3-1,6 Beta Glucan; Imprime PGG) in Combination with Cetuximab and Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer." Investigational New Drugs 35, no. 3 (2017). https://doi.org/10.1007/s10637-017-0450-3.
MLA-Zitierstil (9. Ausg.)Thomas, Michael. "A Randomized, Open-label, Multicenter, Phase II Study Evaluating the Efficacy and Safety of BTH1677 (1,3-1,6 Beta Glucan; Imprime PGG) in Combination with Cetuximab and Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer." Investigational New Drugs, vol. 35, no. 3, 2017, https://doi.org/10.1007/s10637-017-0450-3.